Home > Cardiology > ACC 2021 > Heart Failure and Cardiomyopathy > Novel use of ivabradine in reversible cardiomyopathy

Novel use of ivabradine in reversible cardiomyopathy

Presented By
Dr Eric Torkildsen, Lehigh Valley Health Network, USA
Conference
ACC 2021
Ivabradine may reduce the risk of tachycardia-induced cardiomyopathy when used in refractory cases of tachycardia, as was suggested by findings from a case report [1]. Paragangliomas are rare tumours that result in persistent tachycardia and hypertension. Dr Eric Torkildsen (Lehigh Valley Health Network, PA, USA) shared a case report of a 62-year-old man with a history of metastatic hereditary paraganglioma, non-ischaemic cardiomyopathy with recovered ejection fraction, and recent pericardial effusion, who presented with worsening dyspnoea and sinus tachycardia. Echocardiographic findings included global hypokinesis, no evidence of re-accumulation of pericardial fluid, and a reduced ejection fraction of 20–25%. Angiographic findings demonstrated non-obstructive disease. Based on these findings, the patient was diagnosed with a hyperadrenergic state secondary to the hereditary paraganglioma. Management with metoprolol succinate, phenoxybenzami...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on